Search results for: Human IL-1 R4 ELISA ELISA
#18928158 // To Up
Systemic and intraperitoneal proinflammatory cytokines profiles in patients on chronic peritoneal dialysis.
Cytokines are essential mediators of immune response and inflammatory reactions. Patients with chronic renal failure and on Continuous Ambulatory Peritoneal Dialysis commonly present abnormalities of immune function related to impaired kidney function, accumulation of uremic toxins and bioincompatibility of peritoneal dialysis solutions. Aim of this study was to examine effects of the CAPD solutions (standard v.s. biocompatible), as well as dialysis duration upon the local and systemic profile of the pro-inflammatory cytokines (IL-1, TNF and IL-6) in patients on CAPD. The cross-sectional study included 44 CAPD patients (27 M and 17 F, average mean age 57.12+/-16.66), of whom 21 patients were on the standard solutions (A.N.D.Y.Disc) for peritoneal dialysis and 23 on the biocompatible solutions (Gambrosol bio trio, Stay Safe balance). The average dialysis treatment period was 3.59+/-2.67 years. In all CAPD patients dialysed longer than 6 months, levels of IL-1. TNF and IL-6 in the serum and dialysis effluent were analysed in the phase without acute infection-related complications (CAPD peritonitis, infection of the catheter exit-site, other acute infections). The control group included 20 patients with the CRF (stage IV and V) whose serum levels of the examined cytokines were also determined. Levels of the inflammatory cytokines were measured by commercial specific ELISA kits (BioSource, Camarillo, California, USA). Statistical analysis of the obtained results was performed by commercial statistics PC software (Stat for Windows, R.4.5. SAD). The serum IL-1 and IL-6 levels were not statistically significantly different in patients on CAPD, irrespective of the type of the used dialysis solutions and in the control group of patients with CRF. The serum TNF levels, unlike IL-1 and IL-6, were statistically significantly higher in patients on CAPD in comparison with the control group of patients (13.203.23 v.s. 5.594.54, p< 0.001, Mann Whitney test). The serum and effluent IL-1 levels in patients on CAPD within one and longer than one year of dialysation did not significantly differ, but the effluent IL-6 levels were significantly higher than in the serum of both groups of patients, that is, effluent IL-6 levels in CAPD patients dialysed more than one year was significantly higher in comparison with those in patients dialysed within a year. Both serum and intraperitoneal levels of the examined cytokines did not significantly differ in patients on the standard and biocompatible solutions, regardless of the present trend toward decrease of intraperitoneal IL-6 levels in patients on biocompatible solutions. Residual renal funcion and number of CAPD peritonitis did not have any important impact upon the serum and IP levels of the examined ctokynes. Elevated serum TNF levels and significant local IL-6 production in our CAPD patients indirectly confirm importance of peritoneal dialysis in amplification of the chronic inflammation substantially depend on the duration of dialysis treatment.Doko Maksić, Miodrag Colić, Verica Stanković-Popović, Milorad Radojević, Dubravko Bokonjić
1099 related Products with: Systemic and intraperitoneal proinflammatory cytokines profiles in patients on chronic peritoneal dialysis.
16 Arrays/Slide100ug12 50 UG16 Arrays/Slide16 Arrays/Slide16 Arrays/Slide16 Arrays/Slide1 mg10mg1 mg5ugRelated Pathways
#12508770 // To Up
Expression of TNF-related apoptosis inducing ligand (TRAIL) on infiltrating cells and of TRAIL receptors on salivary glands in patients with Sjögren's syndrome.
Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) induces apoptosis of tumor cells but not normal cells; its role in normal non-transformed tissues is unknown.R Matsumura, K Umemiya, M Kagami, H Tomioka, E Tanabe, T Sugiyama, M Sueishi, N Kayagaki, H Yagita, K Okumura
2112 related Products with: Expression of TNF-related apoptosis inducing ligand (TRAIL) on infiltrating cells and of TRAIL receptors on salivary glands in patients with Sjögren's syndrome.
2 Pieces/Box2 Pieces/Box300 units96 tests1 mg2 Pieces/Box10 ug96 tests2 Pieces/Box100 μgRelated Pathways
Contact Us:
Belgium
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
[email protected]
France
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
[email protected]
Germany
GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
[email protected]
United Kingdom
GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
[email protected]
Also in
Luxembourg +35220880274
Schweiz Züri +41435006251
Danmark +4569918806
Österreich +43720880899
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
Poland
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
[email protected]
skype gentaurpoland
Nederland
GENTAUR Nederland BV
Kuiper 1
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
[email protected]
Italy
GENTAUR SRL
IVA IT03841300167
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
[email protected]
Spain
GENTAUR Spain
Tel 0911876558
[email protected]
Bulgaria
GENTAUR Bulgaria
53 Iskar Str. 1191 Kokalyane, Sofia
Sofia 1000
Tel 0035924682280
Fax 0035929830072
[email protected]